Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea flag South Korea · Delayed Price · Currency is KRW
14,510
-880 (-5.72%)
Apr 28, 2026, 3:30 PM KST
163.58%
Market Cap 1.40T
Revenue (ttm) 3.52B
Net Income (ttm) -22.13B
Shares Out 96.50M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,560,076
Average Volume 2,004,052
Open 15,450
Previous Close 15,390
Day's Range 14,500 - 15,500
52-Week Range 4,325 - 21,500
Beta 1.06
RSI 52.49
Earnings Date May 14, 2026

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2000
Employees 69
Stock Exchange KOSDAQ
Ticker Symbol 048410
Full Company Profile

Financial Performance

In 2025, Hyundai Bioscience's revenue was 3.52 billion, a decrease of -76.63% compared to the previous year's 15.05 billion. Losses were -22.13 billion, 219.3% more than in 2024.

Financial Statements

News

There is no news available yet.